Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Jun 15;19(12):3259-67.
doi: 10.1158/1078-0432.CCR-12-3886. Epub 2013 Apr 25.

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

A Ari Hakimi  1 , Irina Ostrovnaya, Boris Reva, Nikolaus Schultz, Ying-Bei Chen, Mithat Gonen, Han Liu, Shugaku Takeda, Martin H Voss, Satish K Tickoo, Victor E Reuter, Paul Russo, Emily H Cheng, Chris Sander, Robert J Motzer, James J Hsieh; ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators
Affiliations
Multicenter Study

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network

A Ari Hakimi et al. Clin Cancer Res. .

Abstract

Purpose: To investigate the impact of newly identified chromosome 3p21 epigenetic tumor suppressors PBRM1, SETD2, and BAP1 on cancer-specific survival (CSS) of 609 patients with clear cell renal cell carcinoma (ccRCC) from 2 distinct cohorts.

Experimental design: Select sequencing on 3p tumor suppressors of 188 patients who underwent resection of primary ccRCC at the Memorial Sloan-Kettering Cancer Center (MSKCC) was conducted to interrogate the genotype-phenotype associations. These findings were compared with analyses of the genomic and clinical dataset from our nonoverlapping The Cancer Genome Atlas (TCGA) cohort of 421 patients with primary ccRCC.

Results: 3p21 tumor suppressors are frequently mutated in both the MSKCC (PBRM1, 30.3%; SETD2, 7.4%; BAP1, 6.4%) and the TCGA (PBRM1, 33.5%; SETD2, 11.6%; BAP1, 9.7%) cohorts. BAP1 mutations are associated with worse CSS in both cohorts [MSKCC, P = 0.002; HR 7.71; 95% confidence interval (CI)2.08-28.6; TCGA, P = 0.002; HR 2.21; 95% CI 1.35-3.63]. SETD2 are associated with worse CSS in the TCGA cohort (P = 0.036; HR 1.68; 95% CI 1.04-2.73). On the contrary, PBRM1 mutations, the second most common gene mutations of ccRCC, have no impact on CSS.

Conclusion: The chromosome 3p21 locus harbors 3 frequently mutated ccRCC tumor suppressor genes. BAP1 and SETD2 mutations (6%-12%) are associated with worse CSS, suggesting their roles in disease progression. PBRM1 mutations (30%-34%) do not impact CSS, implicating its principal role in the tumor initiation. Future efforts should focus on therapeutic interventions and further clinical, pathologic, and molecular interrogation of this novel class of tumor suppressors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

Motzer - Consultancy from Pfizer; and Research Funding from Pfizer, Novartis, Glaxo Smith Kline, Bristol-Myers Squibb, Aveo and Eisai.

Figures

Figure 1
Figure 1
A: Chromosome 3 map showing geographic proximity of the frequently mutated 3p tumor suppressors, and GISTIC copy number plot demonstrating heterozygous loss of a large segment of 3p in ~90% of the TCGA cohort. Blue color denotes copy number loss, and red –denotes copy number gain. B: Mutation heat map of MSKCC and TCGA cohorts highlights similar mutation frequencies and co-occurrences of the 3p tumors suppressors in both cohorts. C: Mutation percentages by type shows similar patterns in both cohorts (truncating = frameshift, nonsense, or essential splice site).
Figure 2
Figure 2
Competing risk cumulative incidence curves for the MSKCC cohort (n=188) DOD = death of disease.
Figure 3
Figure 3
Competing risk cumulative incidence curves for the TCGA cohort (n=421) DOD = death of disease.
Figure 4
Figure 4
A: Box plots demonstrate the statistically significant incremental increase of purported tumor suppressor genes (TSG) as defined by mutations occurring in the setting of copy number loss across the ccRCC genome. Values in parentheses represent median TSG mutation counts. B: Percentage of TCGA tumors with 3p TSG’s mutated as defined by increasing tumor size, nuclear grade, and AJCC stage. C: Fold change in mutation (%) frequency for 3p TSGs. Note the marked increase in BAP1 mutations with both advanced tumor grade and stage, and the trend in SETD2 mutations for advanced stage.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62:10–29. - PubMed
    1. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. The Journal of urology. 2005;173:48–51. - PubMed
    1. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. The Journal of urology. 2002;168:2395–400. - PubMed
    1. Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. The Journal of urology. 2007;177:477–80. - PubMed
    1. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25:1316–22. - PubMed

Publication types

MeSH terms